E
Windtree Therapeutics, Inc.
WINT
$1.30
$0.075.69%
E
Sell
7/31/2024Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 7/31/2024 due to an increase in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 7/31/2024 due to an increase in the volatility index and total return index.
E
Sell
7/16/2024Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 7/16/2024 due to a decline in the volatility index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 7/16/2024 due to a decline in the volatility index.
E
Sell
6/26/2024Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 6/26/2024 due to an increase in the volatility index.
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 6/26/2024 due to an increase in the volatility index.
E
Sell
6/7/2024Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 6/7/2024 due to a decline in the volatility index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 6/7/2024 due to a decline in the volatility index.
E
Sell
6/4/2024Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 6/4/2024 due to an increase in the volatility index.
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 6/4/2024 due to an increase in the volatility index.
E
Sell
5/16/2024Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 5/16/2024 due to a decline in the volatility index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 5/16/2024 due to a decline in the volatility index.
E
Sell
4/29/2024Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 4/29/2024 due to an increase in the volatility index.
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 4/29/2024 due to an increase in the volatility index.
E
Sell
4/4/2024Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 4/4/2024 due to a decline in the volatility index, solvency index and total return index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 4/4/2024 due to a decline in the volatility index, solvency index and total return index.
E
Sell
3/15/2024Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 3/15/2024 due to an increase in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 3/15/2024 due to an increase in the volatility index and total return index.
E
Sell
2/28/2024Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 2/28/2024 due to a decline in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 2/28/2024 due to a decline in the volatility index and total return index.
E
Sell
2/8/2024Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 2/8/2024 due to an increase in the volatility index.
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 2/8/2024 due to an increase in the volatility index.
E
Sell
1/23/2024Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 1/23/2024 due to a decline in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 1/23/2024 due to a decline in the volatility index and total return index.
E
Sell
12/26/2023Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 12/26/2023 due to an increase in the volatility index.
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 12/26/2023 due to an increase in the volatility index.
E
Sell
12/8/2023Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 12/8/2023 due to a decline in the volatility index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 12/8/2023 due to a decline in the volatility index.
E
Sell
11/17/2023Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 11/17/2023 due to an increase in the volatility index.
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 11/17/2023 due to an increase in the volatility index.
E
Sell
11/9/2023Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 11/9/2023 due to a decline in the volatility index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 11/9/2023 due to a decline in the volatility index.
E
Sell
10/20/2023Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 10/20/2023 due to an increase in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 10/20/2023 due to an increase in the volatility index and total return index.
E
Sell
10/4/2023Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 10/4/2023 due to a decline in the volatility index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 10/4/2023 due to a decline in the volatility index.
E
Sell
9/15/2023Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 9/15/2023 due to an increase in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 9/15/2023 due to an increase in the volatility index and total return index.
E
Sell
8/29/2023Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 8/29/2023 due to a decline in the volatility index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 8/29/2023 due to a decline in the volatility index.
E
Sell
8/10/2023Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 8/10/2023 due to an increase in the solvency index and volatility index. The quick ratio increased from 1.53 to 3.02, and debt to equity declined from 2.19 to 1.39.
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 8/10/2023 due to an increase in the solvency index and volatility index. The quick ratio increased from 1.53 to 3.02, and debt to equity declined from 2.19 to 1.39.
E
Sell
8/8/2023Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 8/8/2023 due to a decline in the volatility index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 8/8/2023 due to a decline in the volatility index.
E
Sell
7/20/2023Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 7/20/2023 due to an increase in the volatility index.
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 7/20/2023 due to an increase in the volatility index.
E
Sell
7/3/2023Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 7/3/2023 due to a decline in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 7/3/2023 due to a decline in the volatility index and total return index.
E
Sell
6/13/2023Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 6/13/2023 due to an increase in the volatility index.
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 6/13/2023 due to an increase in the volatility index.
E
Sell
5/25/2023Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 5/25/2023 due to a decline in the volatility index and solvency index. Debt to equity increased from 1.56 to 2.19, and the quick ratio declined from 2.51 to 1.53.
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 5/25/2023 due to a decline in the volatility index and solvency index. Debt to equity increased from 1.56 to 2.19, and the quick ratio declined from 2.51 to 1.53.
E
Sell
5/8/2023Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 5/8/2023 due to an increase in the volatility index.
Windtree Therapeutics, Inc. (WINT) was upgraded to E+ from E on 5/8/2023 due to an increase in the volatility index.
E
Sell
4/21/2023Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 4/21/2023 due to a decline in the volatility index and solvency index. Debt to equity increased from 0.92 to 1.56.
Windtree Therapeutics, Inc. (WINT) was downgraded to E from E+ on 4/21/2023 due to a decline in the volatility index and solvency index. Debt to equity increased from 0.92 to 1.56.
E
Sell
3/14/2023Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 03/14/2023.
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D- from E+ on 02/23/2023.
Windtree Therapeutics, Inc. (WINT) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index and total return index.
D
Sell
11/21/2022Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D- from E+ on 11/21/2022 due to an increase in the growth index and volatility index. Earnings per share increased from -$0.5936 to -$0.1303, EBIT increased 31.13% from -$5.8M to -$4M, and operating cash flow increased 22.04% from -$5.26M to -$4.1M.
Windtree Therapeutics, Inc. (WINT) was upgraded to D- from E+ on 11/21/2022 due to an increase in the growth index and volatility index. Earnings per share increased from -$0.5936 to -$0.1303, EBIT increased 31.13% from -$5.8M to -$4M, and operating cash flow increased 22.04% from -$5.26M to -$4.1M.
E
Sell
8/10/2022Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 8/10/2022 due to a decline in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 8/10/2022 due to a decline in the volatility index and total return index.
D
Sell
7/21/2022Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D- from E+ on 7/21/2022 due to an increase in the volatility index.
Windtree Therapeutics, Inc. (WINT) was upgraded to D- from E+ on 7/21/2022 due to an increase in the volatility index.
E
Sell
7/6/2022Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 7/6/2022 due to a decline in the volatility index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 7/6/2022 due to a decline in the volatility index.
D
Sell
6/14/2022Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D- from E+ on 6/14/2022 due to an increase in the volatility index.
Windtree Therapeutics, Inc. (WINT) was upgraded to D- from E+ on 6/14/2022 due to an increase in the volatility index.
E
Sell
5/27/2022Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 5/27/2022 due to a decline in the volatility index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 5/27/2022 due to a decline in the volatility index.
D
Sell
5/6/2022Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D- from E+ on 5/6/2022 due to an increase in the growth index. Earnings per share increased from -$0.4637 to -$0.29.
Windtree Therapeutics, Inc. (WINT) was upgraded to D- from E+ on 5/6/2022 due to an increase in the growth index. Earnings per share increased from -$0.4637 to -$0.29.
E
Sell
3/15/2022Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 3/15/2022 due to a decline in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 3/15/2022 due to a decline in the volatility index and total return index.
D
Sell
2/23/2022Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D- from E+ on 2/23/2022 due to an increase in the volatility index.
Windtree Therapeutics, Inc. (WINT) was upgraded to D- from E+ on 2/23/2022 due to an increase in the volatility index.
E
Sell
1/26/2022Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 1/26/2022 due to a decline in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 1/26/2022 due to a decline in the volatility index and total return index.
D
Sell
11/15/2021Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D- from E+ on 11/15/2021 due to a noticeable increase in the growth index, solvency index and volatility index. Earnings per share increased from -$1.4189 to -$0.3076, operating cash flow increased 28.66% from -$7.4M to -$5.28M, and EBIT increased 3.23% from -$7.59M to -$7.35M.
Windtree Therapeutics, Inc. (WINT) was upgraded to D- from E+ on 11/15/2021 due to a noticeable increase in the growth index, solvency index and volatility index. Earnings per share increased from -$1.4189 to -$0.3076, operating cash flow increased 28.66% from -$7.4M to -$5.28M, and EBIT increased 3.23% from -$7.59M to -$7.35M.
E
Sell
11/3/2021Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 11/3/2021 due to a decline in the volatility index.
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 11/3/2021 due to a decline in the volatility index.
D
Sell
10/14/2021Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D- from E+ on 10/14/2021 due to an increase in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was upgraded to D- from E+ on 10/14/2021 due to an increase in the volatility index and total return index.
E
Sell
8/6/2021Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 8/6/2021 due to a noticeable decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.5064 to -$1.42, debt to equity increased from 0.19 to 0.29, and operating cash flow declined 22.4% from -$6.05M to -$7.4M.
Windtree Therapeutics, Inc. (WINT) was downgraded to E+ from D- on 8/6/2021 due to a noticeable decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.5064 to -$1.42, debt to equity increased from 0.19 to 0.29, and operating cash flow declined 22.4% from -$6.05M to -$7.4M.
D
Sell
5/21/2021Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 5/21/2021 due to a noticeable decline in the growth index, volatility index and total return index. Operating cash flow declined 33.25% from -$4.54M to -$6.05M, EBIT declined 30.43% from -$6.96M to -$9.08M, and earnings per share declined from -$0.4402 to -$0.5064.
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 5/21/2021 due to a noticeable decline in the growth index, volatility index and total return index. Operating cash flow declined 33.25% from -$4.54M to -$6.05M, EBIT declined 30.43% from -$6.96M to -$9.08M, and earnings per share declined from -$0.4402 to -$0.5064.
D
Sell
5/17/2021Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 5/17/2021 due to an increase in the volatility index.
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 5/17/2021 due to an increase in the volatility index.
D
Sell
4/29/2021Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 4/29/2021 due to a decline in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 4/29/2021 due to a decline in the volatility index and total return index.
D
Sell
4/5/2021Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 4/5/2021 due to an increase in the growth index, volatility index and valuation index. Operating cash flow increased 45.02% from -$8.26M to -$4.54M, earnings per share increased from -$0.5441 to -$0.4402, and EBIT increased 10.81% from -$7.81M to -$6.96M.
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 4/5/2021 due to an increase in the growth index, volatility index and valuation index. Operating cash flow increased 45.02% from -$8.26M to -$4.54M, earnings per share increased from -$0.5441 to -$0.4402, and EBIT increased 10.81% from -$7.81M to -$6.96M.
D
Sell
3/29/2021Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 3/29/2021 due to a decline in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 3/29/2021 due to a decline in the volatility index and total return index.
D
Sell
3/12/2021Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 3/12/2021 due to an increase in the volatility index and valuation index.
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 3/12/2021 due to an increase in the volatility index and valuation index.
D
Sell
2/22/2021Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 2/22/2021 due to a decline in the volatility index.
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 2/22/2021 due to a decline in the volatility index.
D
Sell
2/4/2021Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 2/4/2021 due to an increase in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 2/4/2021 due to an increase in the volatility index and total return index.
D
Sell
1/14/2021Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 1/14/2021 due to a decline in the volatility index.
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 1/14/2021 due to a decline in the volatility index.
D
Sell
12/29/2020Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 12/29/2020 due to an increase in the volatility index.
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 12/29/2020 due to an increase in the volatility index.
D
Sell
12/8/2020Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 12/8/2020 due to a decline in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 12/8/2020 due to a decline in the volatility index and total return index.
D
Sell
11/20/2020Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 11/20/2020 due to an increase in the volatility index and growth index. Earnings per share increased from -$0.6334 to -$0.5441, and EBIT increased 1.8% from -$7.95M to -$7.81M.
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 11/20/2020 due to an increase in the volatility index and growth index. Earnings per share increased from -$0.6334 to -$0.5441, and EBIT increased 1.8% from -$7.95M to -$7.81M.
D
Sell
10/26/2020Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 10/26/2020 due to a decline in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 10/26/2020 due to a decline in the volatility index and total return index.
D
Sell
10/9/2020Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 10/9/2020 due to an increase in the volatility index and valuation index.
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 10/9/2020 due to an increase in the volatility index and valuation index.
D
Sell
9/21/2020Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 9/21/2020 due to a decline in the volatility index.
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 9/21/2020 due to a decline in the volatility index.
D
Sell
9/3/2020Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 9/3/2020 due to an increase in the volatility index and total return index.
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 9/3/2020 due to an increase in the volatility index and total return index.
D
Sell
8/14/2020Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 8/14/2020 due to a significant decline in the efficiency index, growth index and total return index. Net income declined 46.28% from -$6.53M to -$9.56M, earnings per share declined from -$0.477 to -$0.6334, and operating cash flow declined 28.38% from -$5.48M to -$7.04M.
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 8/14/2020 due to a significant decline in the efficiency index, growth index and total return index. Net income declined 46.28% from -$6.53M to -$9.56M, earnings per share declined from -$0.477 to -$0.6334, and operating cash flow declined 28.38% from -$5.48M to -$7.04M.
D
Sell
8/19/2019Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to D from D+ on 8/19/2019 due to a noticeable decline in the growth index, efficiency index and volatility index. Total capital declined 5.04% from $87.45M to $83.04M.
Windtree Therapeutics, Inc. (WINT) was downgraded to D from D+ on 8/19/2019 due to a noticeable decline in the growth index, efficiency index and volatility index. Total capital declined 5.04% from $87.45M to $83.04M.
D
Sell
4/18/2019Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D+ from D on 4/18/2019 due to a large increase in the total return index, volatility index and efficiency index. Total capital increased 921.8% from -$11.08M to $91.09M.
Windtree Therapeutics, Inc. (WINT) was upgraded to D+ from D on 4/18/2019 due to a large increase in the total return index, volatility index and efficiency index. Total capital increased 921.8% from -$11.08M to $91.09M.
D
Sell
4/4/2017Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 4/4/2017 due to a significant increase in the efficiency index and total return index. Net income increased 21.06% from -$8.36M to -$6.6M.
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 4/4/2017 due to a significant increase in the efficiency index and total return index. Net income increased 21.06% from -$8.36M to -$6.6M.
D
Sell
11/16/2016Downgrade
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 11/16/2016 due to a decline in the efficiency index and solvency index. Total capital declined 78.02% from $9.78M to $2.15M, the quick ratio declined from 1.35 to 0.88, and debt to equity increased from -1.64 to -1.09.
Windtree Therapeutics, Inc. (WINT) was downgraded to D- from D on 11/16/2016 due to a decline in the efficiency index and solvency index. Total capital declined 78.02% from $9.78M to $2.15M, the quick ratio declined from 1.35 to 0.88, and debt to equity increased from -1.64 to -1.09.
D
Sell
8/11/2016Upgraded
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 8/11/2016 due to a noticeable increase in the growth index, efficiency index and volatility index. Total revenue increased 41.33% from $75 to $106, earnings per share increased from -$1.6971 to -$1.29, and net income increased 23.57% from -$13.9M to -$10.62M.
Windtree Therapeutics, Inc. (WINT) was upgraded to D from D- on 8/11/2016 due to a noticeable increase in the growth index, efficiency index and volatility index. Total revenue increased 41.33% from $75 to $106, earnings per share increased from -$1.6971 to -$1.29, and net income increased 23.57% from -$13.9M to -$10.62M.
D
Sell
3/11/2016Downgrade
Discovery Laboratories Inc. (DSCO) was downgraded to D- from D on 3/11/2016 due to a significant decline in the total return index, volatility index and solvency index. Debt to equity increased from -6.98 to 1.4.
Discovery Laboratories Inc. (DSCO) was downgraded to D- from D on 3/11/2016 due to a significant decline in the total return index, volatility index and solvency index. Debt to equity increased from -6.98 to 1.4.
D
Sell
5/22/2014Downgrade
Discovery Laboratories Inc. (DSCO) was downgraded to D from D+ on 5/22/2014 due to a decline in the efficiency index, growth index and solvency index. Total revenue declined 57.53% from $73 to $31, debt to equity increased from 0.32 to 0.39, and earnings per share declined from -$0.1604 to -$0.1354.
Discovery Laboratories Inc. (DSCO) was downgraded to D from D+ on 5/22/2014 due to a decline in the efficiency index, growth index and solvency index. Total revenue declined 57.53% from $73 to $31, debt to equity increased from 0.32 to 0.39, and earnings per share declined from -$0.1604 to -$0.1354.
D
Sell
5/19/2014Downgrade
Discovery Laboratories Inc. (DSCO) was downgraded to D+ from C- on 5/19/2014 due to a large decline in the volatility index.
Discovery Laboratories Inc. (DSCO) was downgraded to D+ from C- on 5/19/2014 due to a large decline in the volatility index.
C
Hold
5/2/2014Upgraded
Discovery Laboratories Inc. (DSCO) was upgraded to C- from D+ on 5/2/2014 due to an increase in the total return index.
Discovery Laboratories Inc. (DSCO) was upgraded to C- from D+ on 5/2/2014 due to an increase in the total return index.
D
Sell
4/17/2014Downgrade
Discovery Laboratories Inc. (DSCO) was downgraded to D+ from C- on 4/17/2014 due to a decline in the total return index.
Discovery Laboratories Inc. (DSCO) was downgraded to D+ from C- on 4/17/2014 due to a decline in the total return index.
C
Hold
3/21/2014Upgraded
Discovery Laboratories Inc. (DSCO) was upgraded to C- from D on 3/21/2014 due to a large increase in the volatility index, solvency index and growth index. The quick ratio increased from 1.87 to 7.28, debt to equity declined from 1.18 to 0.32, and total revenue increased 21.67% from $60 to $73.
Discovery Laboratories Inc. (DSCO) was upgraded to C- from D on 3/21/2014 due to a large increase in the volatility index, solvency index and growth index. The quick ratio increased from 1.87 to 7.28, debt to equity declined from 1.18 to 0.32, and total revenue increased 21.67% from $60 to $73.
NASDAQ
04/04/2025 4:00PM Eastern
Quotes delayed
